"Everything Can Be Improved"

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 1
Volume 16
Issue 1

redesign, 15 years

"Everything Can Be Improved" —C.W. Barron

Dear Reader:

As Oncology NEWS International enters its 15th year of publication, our editorial mission remains the same, to provide comprehensive meeting and news coverage to today's busy oncologist. Because the practice of oncology is ever-changing and improving, we have adapted and fine-tuned Oncology NEWS International to ensure that we too improve and remain on top of your informational needs.

With this issue you will find a more relevant and enticing layout, and coverage of more than 30 reports and features from meetings, presentations, and relevant literature. Look for these enhancements, too:

  • reporting key findings and vital information

  • expert commentaries highlighting clinical relevance

  • controversies and opinions on current oncology issues plus Reports from Peer Reviewed Journals, offering summaries of original research;

Fast Facts, communicating important data, quickly and succinctly; and greater coverage of controversial issues within the oncology community.

Whether you are working in Lung, Breast, Colorectal, Prostate Cancer, or Hematology, or all of these areas, you'll find the popular "Focus On" series a great way to keep abreast of the latest advances and developments in particular disease states. Each department is color coded for easy identification. Test your clinical knowledge with Diagnostic Dilemma and don't forget to read Cancer Care & Economics, edited by Joe Bailes, to keep up on all the happenings in the ever-changing reimbursement arena.

We wish you a happy 2007 and are looking forward to working with you to ensure that Oncology NEWS International continues to provide the high-quality reports and credibility you need.

E-mail us at the addresses below and be sure to visit us online at www.cancernetwork.com.

Let us know what you think.

June Skinner
Executive Editor
jskinner@cmp.com
Cara H. Glynn
Editorial Director
cglynn@cmp.com
Beth Scholz
Publisher
bscholz@cmp.com

Recent Videos
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Related Content